Asia Pacific single cell multiomics market will grow by 21.8% annually with a total addressable market cap of $ 16,032.0 million over 2022-2031, driven by the rising prevalence of chronic diseases along with the aging population, the widespread product adoption for visualization and analysis, technological advancements along with the rising R&D investment, and the significant growth in the pharmaceutical industry especially personalized medication.
Highlighted with 36 tables and 76 figures, this 149-page report "Asia Pacific Single Cell Multiomics Market 2021-2031 by Product Type (Instruments, Consumables, Software), Omics Type (SCG, SCT, SCP, SCM), Application (Clinical Research, Translation Research, Synthetic Biology), Sample Type (Human, Animal, Microbial), Workflow (Single-Cell Isolation and Dispensing, Single-Cell Analysis), End User (Research and Academic Laboratories, Biopharma and Biotech Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire Asia Pacific single cell multiomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific single cell multiomics market in every aspect of the classification from perspectives of Product Type, Omics Type, Application, Sample Type, Workflow, End User, and Country.
Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Instruments
• Consumables
• Software
Based on Omics Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Single Cell Genomics (SCG)
• Single Cell Transcriptomics (SCT)
• Single Cell Proteomics (SCP)
• Single Cell Metabolomics (SCM)
By Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Clinical Research
o Oncology
o Cell Therapy
o Immunology
o Neurology
o Cell Biology
o Other Types of Clinical Research
• Translation Research
• Synthetic Biology
By Sample Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Human Samples
o Cancer Tissues
o Stem Cells
o Immune Cells
o Brain Cells
o Other Human Samples
• Animal Samples
• Microbial Samples
By Workflow, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Single-Cell Isolation and Dispensing
o Fluorescence-Activated Cell Sorting (FACS)
o Microfluidics
o Magnetic-Activated Cell Sorting (MACS)
o Random Seeding
o Manual Cell Picking
o Laser Capture Microdissection
o Other Technologies of Single-Cell Isolation and Dispensing
• Single-Cell Analysis
o Polymerase Chain Reaction
o Next-Generation Sequencing
o Mass Cytometry
o Mass Spectrometry
o Other Technologies of Single-Cell Analysis
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Research and Academic Laboratories
• Biopharmaceutical and Biotech Companies
• Contract Research Organizations (CROs)
• Other End Users
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Omics Type, Workflow and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
10x Genomics, Inc.
1CellBio, Inc.
Becton, Dickinson and Company
Berkeley Lights, Inc.
BGI Genomics Co., Ltd.
Bio-Rad Laboratories, Inc.
Bio-Techne Corporation
BioTuring, Inc.
Danaher Corporation (Cytiva Life Sciences)
Dolomite Bio
Fluidigm Corporation
Fluxion Biosciences
Illimina, Inc
Mission Bio, Inc.
Namocell, Inc.
NanoString Technologies, Inc.
Parse Biosciences, Inc.
Proteona
Qiagen N.V.
RareCyte, Inc.
Scipio Biosciences SAS
Shilps Sciences
Takara Bio Inc. (Takara Holdings)
Thermo Fisher Scientific Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)